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SUMMARY: Endotoxin shock and contact system activation were used to study effects of hirudin, 
antithrombin III, eglin C, aprotinin, and [Argl5]-aprotinin in anesthetized pigs. Alterations in the 
systemic and pulmonary circulation were in part prevented by administration of the inhibitors. 
INTRODUCTION 
The proteolytic cascade systems of plasma are activated both in patients with septic shock and in 
animals with endotoxin-induced shock. In severe inflammation, digestive proteases are released from 
inflammatory cells such as phagocytes. In order to study potential therapeutic applications of various 
protease inhibitors we investigated their effect in experimental shock, induced by bacterial lipopoly-
saccharide (LPS) or dextran sulfate (DXS), an agent which activates the contact system of blood 
coagulation. 
MATERIALS AND METHODS 
We used miniature pigs (body weight «20 kg) under general anesthesia and controlled ventilation. 
All animal procedures were approved by the Regierung von Oberbayern and complied with the 
Tierschutzgesetz in der Fassung vom 18. 8. 1986. We infused LPS from S. abortus equi for 6 h or for 
8 h, or DXS in a dose of 5 mg/kg in 1 h or saline. We used the following proteinase inhibitors, each 
in randomized, controlled trials: a purified human antithrombin III-heparin complex (AT III-heparin) 
or recombinant hirudin for thrombin; recombinant eglin C for PMN elastase; bovine aprotinin or 
recombinant [Argl5]-aprotinin for plasma kallikrein. Case numbers were mentioned in the legends. 
For full experimental details, the reader is referred to the original descriptions (1, 2, 3 , 4). [Arg 15]-
aprotinin was given intravenously as a bolus before and as a continuous infusion during stimulation 
with dextran sulfate. The study design and plasma levels thus achieved are given in table 1. 
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Table 1. Dextran sulfate (DXS) and [Argl5]-aprotinin: Doses and plasma concentrations 
[Arg 15]-aprotinin Plasma 
Activation Bolus Injection Continuous Infusion Level at 
Group n with (mg) (mg) 1 h OiM) 
NaCl Control 3 NaCl 0 0 0 
A15A Control 2 NaCl 120 240 3.8 
DXS + 360 mg 5 DXS 120 240 1.4 
DXS + 180 mg 5 DXS 60 120 0.8 
DXS + 90 mg 5 DXS 30 60 0.7 
DXS + 45 mg 5 DXS 15 30 0.2 
DXS Control 5 DXS 0 0 0 
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Time 00 Time (h) Figure l. Effect of hirudin in LPS shock. Upper left: Soluble fibrin concentration in plasma. Upper 
right: Pulmonary vascular resistance (PVR). Lower left: Peak airways opening pressure. Lower 
right: Extravascular lung water (EVLW). All four parameters were lower in hirudin-treated animals 
(n= 18) than in control animals (n = 18). 
The total intravascular protein content was calculated as the product of plasma volume as assessed by 
Evans' Blue dye dilution times total protein concentration in plasma (Biuret reaction), corrected for 
body weight. The difference between measurements obtained at baseline and after 4 h represents the 
loss of intravascular protein. Cardiac output and extravascular lung water were measured by single 
indicator thermodilution (Model 9310, Edwards), the pulmonary vascular pressure with a Swan-Ganz 
catheter, and the systemic blood pressure with a catheter in the abdominal aorta. 
Effects of Protease Inhibitors 423 
M.l-1 
I — I — I 1 1 — I — I — 
0 1 2 3 4 6 6 
Figure 2. Effect of a purified complex between 
human antithrombin III and heparin in LPS shock. 
The formation of monomeric fibrin was almost 
completely blocked in the AT III-heparin-treated 
animals (n = 8) as compared to the control animals 
(n=9). 
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Kinin-containing kininogen was determined on the basis of the amount of kinin releasable in plasma 
samples by incubation with trypsin. C3a in plasma was measured by radioimmunoassay. In the 
hirudin and AT III-heparin studies, soluble fibrin was detected using a functional assay (5). In the 
aprotinin study, fibrin monomer was detected in plasma by an enzyme immunoassay using a 
monoclonal antibody to the N-terminal a-chain of fibrin. 
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Figure 3. Effect of eglin C in LPS shock. Left: Decrease in intravascular protein content (IVP). 
Eglin-treated animals (n=18) had substantially less decrease in IVP than control animals (n=18). 
Right: Alveolar-arterial 02 pressure gradient (A-aD02). There was no difference in A-aD02 between 
controls and eglin-treated animals. 
RESULTS 
Hirudin (0.1 /iM plasma concentration) reduced fibrin formation and ameliorated LPS-induced lung 
dysfunction (cf. fig. 1). AT III-heparin (120% of normal AT III activity in plasma) blocked fibrin 
formation (cf. fig. 2), but did not improve respiratory dysfunction. Eglin C (2 jiM) reduced the loss of 
protein from the intravascular space, but did not affect respiratory dysfunction (cf. fig. 3). 
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Figure 4. Effect of aprotinin in LPS shock. Upper left: Kinin-containing total kininogen. There was 
no difference in turn-over of kininogen between aprot in in-treated animals (n=10) and control animals 
(n= 10). Upper right: Mean arterial blood pressure (MABP). Aprotinin-treated animals had higher 
blood pressure than control animals. Lower left: Monomeric fibrin concentration in plasma. Lower 
right: Complement fragment 3a (C3a) concentration in plasma. Aprotinin-treated animals had 
substantially lower fibrin levels and, at least initially, lower C3a levels than control animals. 
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Figure 5. Effect of [Argl5]-aprotinin in dextran 
sulfate (DXS)-induced hypotension. Time from 
onset of DXS infusion to 50% arterial 
hypotension was progressively delayed with 
increased doses of [Argl5]-aprotinin; hypotension 
was completely abolished in the highest dose 
administered. 
Aprotinin (10 /iM) reduced LPS-induced hypotension, fibrin formation and C3a formation, but not the 
decrease in plasma kininogen levels (cf. fig. 4). [Argl5]-aprotinin (1.4 /xM) blocked DXS-induced 
arterial hypotension (cf. fig. 5) and kininogen breakdown. 
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DISCUSSION 
Hirudin had the anticipated effect on fibrinogen degradation and fibrin formation. Furthermore, it 
reduced some of the effects of LPS on lung function. In contrast, antithrombin III in complex with 
heparin had no effect on respiratory dysfunction, although it was even better at inhibiting fibrinogen 
degradation and completely blocked fibrin formation. Studies with heparin alone in a similar model 
revealed analogous results (6). Although these studies were not designed specifically to compare the 
effectiveness of hirudin and antithrombin III, we assume that hirudin in contrast to antithrombin III 
was able to block some of the cellular effects of thrombin (mediated by formation of thromboxane (7) 
or endothelin (8) or directly (9)), and this is a possible reason why hirudin ameliorated LPS-induced 
lung dysfunction and reduced' the increase in pulmonary vascular resistance. 
Eglin C was found only to have an effect in the systemic circulation where it reduced protein 
extravasation. Similar effects have been observed in two other independent experiments (10, 11). 
Three possible explanations exist for this finding. PMN elastase can influence the metabolism of 
arachidonic acid (12). Chymase, another enzyme that is inhibited by eglin C, is involved in mast cell 
degranulation, and it is possible that the observed effects of eglin C have nothing to do with PMN 
elastase, but rather with inhibition of mast cell degranulation (13). The third possibility is an action 
mediated via cytokines. Human alpha-1 antitrypsin (14) and, similarly, eglin C (A. Wendel, Konstanz, 
FRG, personal communication) are able to block a final proteolytic step in the generation of bioactive 
tumor necrosis factor a. The absence of an effect of eglin C on respiratory dysfunction suggests that 
the endotoxin-induced lung damage in our model was produced by other mechanisms than the release 
of PMN elastase. 
Aprotinin produced effects that suggest that the contact system of plasma was activated in LPS shock. 
Hypotension and vasodilation are typical effects of bradykinin. Complement activation is associated 
with activation of the contact system. The observed effect on the C3a plasma levels however might 
also have been produced by plasmin inhibition, and the aprotinin plasma levels in our experiment were 
far higher than what is necessary to achieve plasmin inhibition. Significant was the finding that fibrin 
formation, assessed by an immunologic method, was reduced - a fact that underscores the importance 
of this pathway for coagulation activation in LPS shock. 
[Argl5]-aprotinin is an aprotinin homologue with excellent inhibition of plasma kallikrein (15). In our 
in vivo model using infusion of dextran sulfate it blocked at lower concentrations than aprotinin (16). 
It should be useful to test whether it has additional protective effects in LPS shock. 
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CONCLUSION 
We have shown that different proteases are involved in different ways in the events during endotoxin 
shock, and that the effect of proteinase inhibition largely depends on the enzyme being inhibited and on 
the relative role of the enzyme in this very complex sequence of events. The impact of enzymes on 
organ dysfunction in shock, however, may depend on their ability to stimulate cells, in addition to 
their cleaving of substrates. 
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